Simcere Pharmaceutical of Nanjing struck a deal with Amgen to co-develop and commercialize four Amgen biosimilars in China. The exact biosimilars were not disclosed, though Amgen said they address needs in inflammation and oncology. Earlier this month, Amgen was approved by the FDA to market a biosimilar to Roche’s Avastin, the first oncology biosimilar approved in the US. Amgen has disclosed a portfolio of six biosimilars and says it has three more in earlier development.
Source: ChinaBio Today
